C-Suite Committee

BioNJ’s Annual C-Suite Summit convenes industry leaders and their teams from companies at all points along the development continuum – early to late stage, public and private, revenue and pre-revenue – to share insights, experiences and strategic thinking around biopharma innovation and the future of health care. Committee members create an agenda and enlist vital stakeholder executives to address emerging science, technologies and the global challenges and opportunities impacting the journey from development to delivery of innovative treatments to Patients.

Committee Members:

EY –
Arda Ural, Ph.D., MSc, MBA, Partner, American Industry Market Leader US East HSW Market Segment Leader

Agile Therapeutics – Paul Korner, MD, MBA, Chief Medical Officer
Ascendia Pharma – Robert Bloder, Chief Business Officer
– Alain Van Loo, Founder
Avotres – Emmie Fan, Chief Business Officer
BioBridges – Marc Beaver, Senior Director, Client Services
BioBridges – Marci Newnham, Director, Client Services
CohnReznick LLP – Ravi Raghunathan, CPA, Partner, Life Sciences Industry Leader
Manya Deehr, JD (In-transition)
Deloitte – Brian Wilcomes, CPA, Partner
EisnerAmper LLP – John Pennett, CPA, Partner-in-Charge, National Life Sciences & Technology Group
EY – Tony Torrington, CPA, Partner
Focus-X Therapeutics, Inc. – Fa Liu, Ph.D., CEO
GSK – Sri Ramaswami, Vice President, Head, U.S. Commercial Communications 
– Brion Brandes, VP, Commercial Solutions, Life Sciences
Javan Engineering – Brett Busconi, VP, Client Development
Kenox Pharmaceuticals – Sitaram Velaga, Ph.D., CEO
Korn Ferry International
– Jan Campbell, MBA, Senior Client Partner
– Marshall Calman, MBA, PCC, Co-Founder & Principal
LeaderStrong – Jack Levitt, MBA, EMTM, Co-Founder & Principal
Marsh, Inc. – Annie Devine, Senior Sales Executive
McKinsey & Company – Emma Kemble, Engagement Manager
McKinsey & Company – Adam Knepp, Ph.D., Associate Partner
McKinsey & Company – Peter Pfeiffer, Ph.D., Senior Partner
Melinta Therapeutics – Jisoo Park, Head of Business Development, M&A and Strategy
Merck – Mitzi Conners, Executive Director, Head of Operations, MRL Business Development & Licensing
Nevakar – Raul Trillo, MD, MBA, Chief Commercial Officer
Novartis – Dawn Bell, PharmD, Global Head, Strategic Partnerships
RSM US LLP – Joe Wolfe, Life Sciences Business Development Director
Strategies for Success International – Tracy Tyler, MBA, Founder & Managing Director
Thermo Fisher Scientific – Kristin Roosevelt, Industry Director – Biotechnology
WhizAI – Rohit Vashist, CEO

BioNJ Committee Policy
Each BioNJ Committee has two Co-Committee Chairpersons, as identified and selected by BioNJ leadership and the working Committee. Each Committee Chairperson is elected for a two-year term. At BioNJ’s discretion, one Chairperson will transition off annually to allow for continuity of leadership.